61 related articles for article (PubMed ID: 9215828)
1. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Goey SH; Punt CJ; Proebstle TM; Salzmann R; Scheibenbogen C; Schadendorf D; Liénard D; Enk A; Dummer R; Hantich B; Geueke AM; Eggermont AM
J Clin Oncol; 1997 Jul; 15(7):2579-88. PubMed ID: 9215828
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
[TBL] [Abstract][Full Text] [Related]
3. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.
Payne MJ; Argyropoulou K; Lorigan P; McAleer JJ; Farrugia D; Davidson N; Kelly C; Chao D; Marshall E; Han C; Wellman S; Middleton MR
J Clin Oncol; 2014 Jan; 32(3):185-90. PubMed ID: 24344211
[TBL] [Abstract][Full Text] [Related]
4. Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.
Garcia-Arumi J; Morral Palau M; Montolio Gil M; Blasco Garrido H; Sararols Ramsay L; Segura García A
Br J Ophthalmol; 2006 Apr; 90(4):516-8. PubMed ID: 16547342
[No Abstract] [Full Text] [Related]
5. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
6. DNA Damage-driven Inflammatory Cytokines: Reprogramming of Tumor Immune Microenvironment and Application of Oncotherapy.
Wang MJ; Xia Y; Gao QL
Curr Med Sci; 2024 Apr; 44(2):261-272. PubMed ID: 38561595
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy.
Ciwun M; Tankiewicz-Kwedlo A; Pawlak D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539570
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma.
Na'ara S; Mukherjee A; Billan S; Gil Z
Onco Targets Ther; 2020; 13():2289-2298. PubMed ID: 32214828
[TBL] [Abstract][Full Text] [Related]
9. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Boudewijns S; Bloemendal M; de Haas N; Westdorp H; Bol KF; Schreibelt G; Aarntzen EHJG; Lesterhuis WJ; Gorris MAJ; Croockewit A; van der Woude LL; van Rossum MM; Welzen M; de Goede A; Hato SV; van der Graaf WTA; Punt CJA; Koornstra RHT; Gerritsen WR; Figdor CG; de Vries IJM
Cancer Immunol Immunother; 2020 Mar; 69(3):477-488. PubMed ID: 31980913
[TBL] [Abstract][Full Text] [Related]
10. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Pedersen M; Westergaard MCW; Milne K; Nielsen M; Borch TH; Poulsen LG; Hendel HW; Kennedy M; Briggs G; Ledoux S; Nøttrup TJ; Andersen P; Hasselager T; Met Ö; Nelson BH; Donia M; Svane IM
Oncoimmunology; 2018; 7(12):e1502905. PubMed ID: 30524900
[No Abstract] [Full Text] [Related]
11. Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.
Ma Q; Shilkrut M; Zhao Z; Li M; Batty N; Barber B
BMC Cancer; 2018 Feb; 18(1):145. PubMed ID: 29409500
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13. Role of IL-2 in cancer immunotherapy.
Jiang T; Zhou C; Ren S
Oncoimmunology; 2016 Jun; 5(6):e1163462. PubMed ID: 27471638
[TBL] [Abstract][Full Text] [Related]
14. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
15. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.
Vörsmann H; Groeber F; Walles H; Busch S; Beissert S; Walczak H; Kulms D
Cell Death Dis; 2013 Jul; 4(7):e719. PubMed ID: 23846221
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.
Dequen P; Lorigan P; Jansen JP; van Baardewijk M; Ouwens MJ; Kotapati S
Oncologist; 2012; 17(11):1376-85. PubMed ID: 23024154
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
18. Sarcomatoid carcinoma of the bladder after simultaneous kidney-pancreas transplant: a case report and review of the literature.
McCrea PH; Chang M; Bailley G; Molinari M
BMJ Case Rep; 2012 Apr; 2012():. PubMed ID: 22605000
[TBL] [Abstract][Full Text] [Related]
19. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
[TBL] [Abstract][Full Text] [Related]
20. Melanoma: a model for testing new agents in combination therapies.
Ascierto PA; Streicher HZ; Sznol M
J Transl Med; 2010 Apr; 8():38. PubMed ID: 20406483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
